Spectroscopic Study of the Basicity of 4,6-Dihydroxypyrimidine Derivatives

Vu, Tuan Q.; Yudin, N. V.; Kushtaev, A. A.; Nguyen, Thanh X.; Maltsev, Sergey A.

doi:10.1021/acsomega.1c00671

Cited by 2 publications

References 35 publications

(61 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Recent Synthetic and Biological Advances in Anti-Cancer Ferrocene-Analogues and Hybrids

Mehra,

Lumb

2023

Advances in Organic Synthesis

View full text Add to dashboard Cite

Cancer is among the most severe risks to the global human population. The enduring crisis of drug-resistant cancer and the limited selectivity of anticancer drugs are significant roadblocks to its control and eradication, requiring the identification of new anticancer entities. The stable aromatic nature, reversible redox properties, and low toxicity of ferrocene revolutionized medicinal organometallic chemistry, providing us with bioferrocene compounds with excellent antiproliferative potential, which has been the focus of persistent efforts in recent years. Substituting the aryl/heteroaryl core for ferrocene in an organic molecule alters its molecular characteristics, including solubility, hydro-/lipophilicity, as well as bioactivities. Ferrocifen (ferrocene analogues of hydroxytamoxifen) has shown antiproliferative potential in both hormone-dependent (MCF-7) and hormone-independent (MDA-MB-231) breast cancer cells. It is now in pre-clinical trials against malignancies. These entities operate through various targets, some of which have been revealed and activated in response to product concentrations. They also react to the cancer cells by diverse mechanisms that can work in concert or in isolation, depending on signaling pathways that promote senescence or death. The behavior of ferrocene-containing hybrids with a range of anticancer targets is explained in this chapter.

show abstract

Recent Synthetic and Biological Advances in Anti-Cancer Ferrocene-Analogues and Hybrids

Mehra,

Lumb

2023

Advances in Organic Synthesis

View full text Add to dashboard Cite

show abstract

The sodium 5-butyl-1,2-diphenyl-6-oxo-1,6-dihydropyrimidine-4-olate quantitative content determination in a standard sample

Kuvaeva

Kolesnik

Levshukova

et al. 2021

Razrabotka i registraciâ lekarstvennyh sredstv

View full text Add to dashboard Cite

Introduction. The standard samples (SS) use is a necessary condition for the medicines' quality control implementation. Their development is an urgent problem for the pharmaceutical industry, especially for new biologically active compounds that can be further used as pharmaceuticals.Aim. This work aim is to establish the 5-butyl-1,2-diphenyl-6-oxo-1,6-dihydro pyrimidone-4-olate sodium quantitative content, for which anti-inflammatory and analgesic activity was previously proven, in a standard sample.Materials and methods. This work aim is to establish the 5-butyl-1,2-diphenyl-6-oxo-1,6-dihydro pyrimidone-4-olate sodium quantitative content, for which anti-inflammatory and analgesic activity was previously proven, in a standard sample. The main method for establishing a substance quantitative content in the SS is the material balance method. The water determination was carried out according to K. Fisher's method (semimicro method). Sulphated ash was determined according to the XIV edition Russian Federation State Pharmacopoeia General Pharmacopoeia Monograph "Sulphated ash". Related impurities and their content were assessed using the HPLC method on a Flexar liquid chromatograph equipped with a diode array detector (Perkin Elmer, USA). The residual solvents' determination was carried out by the headspace method using a gas chromatograph GC-2010Plus Shimadzu with a flame ionization detector. As an additional method for establishing the main component quantitative content, acidimetric titration with the equivalence point potentiometric indication was carried out.Results and discussion. The percentage was determined for the following indicators: water, residual organic solvents, related impurities, sulphated ash. Using the material balance method, it was found that the 5-butyl-1,2-diphenyl-6-oxo-1,6-dihydropyrimidin-4-olate sodium percentage in a standard sample is 96.01 ± 0.50 %. It was found by acidimetric titration that the 5-butyl-1,2-diphenyl-6-oxo 1,6-dihydropyrimidin- 4-olate sodium quantitative content in SS is 95.12 ± 0.02 %. The difference in the certified value can be explained by the fact that during titration, the SS aciform is released, which precipitates in an aqueous medium and contributes to a shift in the equilibrium and pH value. Consequently, the equivalence point is reached somewhat earlier. However, the data are practically comparable, but it is necessary to use the value obtained by the material balance method.Conclusion. A standard sample certification parameters were determined: water content, residual organic solvents, sulphated ash, related impurities. The main component quantitative content was determined using the material balance method and titrimetry (acidimetry with the equivalence point potentiometric indication).

show abstract

Spectroscopic Study of the Basicity of 4,6-Dihydroxypyrimidine Derivatives

Cited by 2 publications

References 35 publications

Recent Synthetic and Biological Advances in Anti-Cancer Ferrocene-Analogues and Hybrids

Recent Synthetic and Biological Advances in Anti-Cancer Ferrocene-Analogues and Hybrids

The sodium 5-butyl-1,2-diphenyl-6-oxo-1,6-dihydropyrimidine-4-olate quantitative content determination in a standard sample

Contact Info

Product

Resources

About